AEBP1
protein-codingAE binding protein 1, the group of MicroRNA protein coding host genes|M14 carboxypeptidases
Gene summary
This gene encodes a member of carboxypeptidase A protein family. The encoded protein may function as a transcriptional repressor and play a role in adipogenesis and smooth muscle cell differentiation. Studies in mice suggest that this gene functions in wound healing and abdominal wall development. Overexpression of this gene is associated with glioblastoma. [provided by RefSeq, May 2013]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~10.2 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0054813
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0054813
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0054813
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0054813
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0054813
Submitter: Genomics England PanelApp
Inheritance Pattern: AR
Disease ID:MONDO:0054813
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Gastrointestinal; Genitourinary; Musculoskeletal
Intervention: Cardiovascular; Gastrointestinal
Rationale: The condition can include manifestations such as bowel rupture and cardiovascular complications including aortic root dilatation, and awareness may allow surveillance, preventative measures, and early management
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to AEBP1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001129.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 244 | 1 | 247 | ||
| missense | 1 | 270 | 20 | 1 | 292 | |
| nonsense | 7 | 5 | 1 | 13 | ||
| start loss | 1 | 1 | ||||
| frameshift | 19 | 7 | 5 | 31 | ||
| splice donor/acceptor (+/-2bp) | 2 | 8 | 3 | 1 | 14 | |
| Total | 28 | 22 | 281 | 265 | 2 | 598 |
Highest pathogenic variant AF is 0.000012440596
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001120.3 | 21 | MANE Select | |
| Ensembl | ENSP00000223357.3 | 21 | MANE Select | |
| Ensembl | ENSP00000410349.1 | 2 | Standard | |
| Ensembl | ENSP00000416568.1 | 1 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Biological Process
- negative regulation of transcription by RNA polymerase II
- skeletal system development
- peptide metabolic process
- muscle organ development
- protein processing
Molecular Function
- RNA polymerase II regulatory region sequence-specific DNA binding
- DNA-binding transcription repressor activity, RNA polymerase II-specific
- DNA-binding transcription factor activity
- transcription corepressor activity
- carboxypeptidase activity
Cellular Component
- extracellular region
- extracellular space
- nucleus
- cytoplasm
- collagen-containing extracellular matrix
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000223357
- Coding exons
- 21
- Length
- 10202
- Individuals with no LoFs
- 124409
- Homozygous LoFs
- 5
- Heterozygous LoFs
- 1332
- Defined
- 125746
- p
- 0.00533
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.00 | 654 | 730 | 0.896 | 0.0000467 | 7495 |
| Missense (PolyPhen) | 222 | 268.07 | 0.82815 | 2638 | ||
| Synonymous | 1.23 | 279 | 306 | 0.911 | 0.0000212 | 2287 |
| Loss of Function | 3.79 | 27 | 58.2 | 0.464 | 0.00000329 | 624 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.0013 | 0.0012 | notable |
| Latino/Admixed American | 0.0035 | 0.0034 | notable |
| Ashkenazi Jewish | 0.0049 | 0.0048 | notable |
| East Asian | 0.00044 | 0.00044 | rare |
| Finnish | 0.0053 | 0.0049 | notable |
| European (Non-Finnish) | 0.0084 | 0.0077 | notable |
| South Asian | 0.0046 | 0.0044 | notable |
| Other | 0.0063 | 0.0059 | notable |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Isoform 1: As a positive regulator of collagen fibrillogenesis, it is probably involved in the organization and remodeling of the extracellualr matrix. {ECO:0000269|PubMed:29606302}.;
- Disease
- DISEASE: Ehlers-Danlos syndrome, classic-like, 2 (EDSCLL2) [MIM:618000]: A variant form of Ehlers-Danlos syndrome, a connective tissue disorder. EDSCLL2 patients show severe joint and skin laxity, osteoporosis affecting the hips and spine, osteoarthritis, soft redundant skin that can be acrogeria-like, delayed wound healing with abnormal atrophic scarring, and shoulder, hip, knee, and ankle dislocations. Additional variable features include gastrointestinal and genitourinary manifestations (bowel rupture, gut dysmotility, cryptorchidism, and hernias), vascular complications (mitral valve prolapse and aortic root dilation), and skeletal anomalies. EDSCLL2 inheritance is autosomal recessive. {ECO:0000269|PubMed:27023906, ECO:0000269|PubMed:29606302}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.150
Intolerance Scores
- LoFtool
- 0.140
- RVIS EVS
- 0.12
- RVIS percentile EVS
- 62.21
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.108
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | High |
| Cancer | Medium | Medium | Medium |